BRISTOL-MYERS SQUIBB COMPANY Cash and Restricted Cash
BRISTOL-MYERS SQUIBB COMPANY (BMY) had Cash and Restricted Cash of $8.72 billion as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-07-30
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $8.72B.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $9.58B.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $10.22B.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $15.73B.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $8.72B 10-Q · filed 2026-07-30 |
| 2026-03-31 | $9.58B 10-Q · filed 2026-04-30 |
| 2025-12-31 | $10.22B 10-Q · filed 2026-07-30 |
| 2025-09-30 | $15.73B 10-Q · filed 2025-10-30 |
| 2025-06-30 | $12.61B 10-Q · filed 2026-07-30 |
| 2025-03-31 | $10.88B 10-Q · filed 2026-04-30 |
| 2024-12-31 | $10.35B 10-Q · filed 2026-07-30 |
| 2024-09-30 | $7.89B 10-Q · filed 2025-10-30 |
| 2024-06-30 | $6.30B 10-Q · filed 2025-07-31 |
| 2024-03-31 | $9.33B 10-Q · filed 2025-04-24 |
| 2023-12-31 | $11.52B 10-K · filed 2026-02-11 |
| 2023-09-30 | $7.57B 10-Q · filed 2024-10-31 |
| 2023-06-30 | $8.43B 10-Q · filed 2024-07-26 |
| 2023-03-31 | $9.05B 10-Q · filed 2024-04-25 |
| 2022-12-31 | $9.32B 10-K · filed 2026-02-11 |
| 2022-09-30 | $7.96B 10-Q · filed 2023-10-26 |
| 2022-06-30 | $10.96B 10-Q · filed 2023-07-27 |
| 2022-03-31 | $12.58B 10-Q · filed 2023-04-27 |
| 2021-12-31 | $14.32B 10-K · filed 2025-02-12 |
| 2021-09-30 | $13.88B 10-Q · filed 2022-10-26 |
| 2021-06-30 | $11.40B 10-Q · filed 2022-07-27 |
| 2021-03-31 | $11.32B 10-Q · filed 2022-04-29 |
| 2020-12-31 | $14.97B 10-K · filed 2024-02-13 |
| 2020-09-30 | $19.86B 10-Q · filed 2021-10-27 |
| 2020-06-30 | $20.36B 10-Q · filed 2021-07-28 |
| 2020-03-31 | $16.25B 10-Q · filed 2021-04-29 |
| 2019-12-31 | $12.82B 10-K · filed 2023-02-14 |
| 2019-09-30 | $30.49B 10-Q · filed 2020-11-05 |
| 2019-06-30 | $28.40B 10-Q · filed 2020-08-06 |
| 2019-03-31 | $7.33B 10-Q · filed 2020-05-07 |
| 2018-12-31 | $6.91B 10-K · filed 2022-02-09 |
| 2017-12-31 | $5.42B 10-K · filed 2021-02-10 |
| 2016-12-31 | $4.24B 10-K · filed 2020-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |